darunavir sandoz 400 mg tabletki powlekane
sandoz gmbh - darunavirum - tabletki powlekane - 400 mg
darunavir sandoz 600 mg tabletki powlekane
sandoz gmbh - darunavirum - tabletki powlekane - 600 mg
darunavir sandoz 800 mg tabletki powlekane
sandoz gmbh - darunavirum - tabletki powlekane - 800 mg
bisoprolol genoptim 1,25 mg tabletki powlekane
synoptis pharma sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 1,25 mg
darunavir sandoz 150 mg tabletki powlekane
sandoz gmbh - darunavirum - tabletki powlekane - 150 mg
nebivolol genoptim 5 mg tabletki
synoptis pharma sp. z o.o. - nebivololi hydrochloridum - tabletki - 5 mg
methadone hydrochloride inn-farm 1 mg/ml roztwór doustny
inn-farm d.o.o., - methadoni hydrochloridum - roztwór doustny - 1 mg/ml
abirateron teva 500 mg tabletki powlekane
teva b.v. - abirateronu octan - tabletki powlekane - 500 mg
abiraterone mylan
mylan ireland limited - octan abirateronu - nowotwory stercza - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone krka
krka, d.d., novo mesto - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.